Monitor the special meeting vote outcome on November 11, 2026. If Proposal 3 passes, expect significant dilution overhang as the $6.10 conversion/exercise price is well above current trading levels, limiting near-term conversion but creating massive future overhang. The authorized share increase (Proposal 2) gives the board blanket authority for further dilutive financings without shareholder votes, which is a persistent bearish signal for a micro-cap biotech with no disclosed revenue or pipeline catalysts.
Price Chart
Executive Summary
GT Biopharma is holding a special meeting on November 11, 2026 to vote on four proposals: (1) cleaning up obsolete preferred stock series from the charter, (2) increasing authorized common shares from 25M to 250M (a 10x increase), (3) approving the issuance of 19.99%+ of outstanding shares under a September 2026 securities purchase agreement (including Series M Preferred Stock conversion and warrants), and (4) adjourning the meeting if needed. The core event is a massive potential dilution — if Proposal 3 passes, private placement investors could control 44-61% of voting power, representing an effective change of control. The authorized share increase (Proposal 2) enables further future dilution without additional shareholder votes.
Key Facts
- Special meeting on November 11, 2026 to vote on 4 proposals
- Proposal 2: increase authorized common shares from 25,000,000 to 250,000,000 (10x increase)
- Proposal 3: approve issuance of 19.99%+ of outstanding shares under September 14, 2026 Securities Purchase Agreement
- Private Placement: $7,750,000 aggregate purchase price for Series M Preferred Stock (stated value $8,611,111.11) plus warrants
- Greenshoe Rights allow additional Series M Preferred Stock purchase up to $34,675,615 stated value for $31,208,054
- If Proposal 3 approved, Series M Preferred Stock convertible into 1,411,651 common shares at $6.10/share
- Common Stock Warrants for additional 1,411,651 shares at $6.10/share, 5-year term
- If Proposal 3 approved and all Series M converted: Private Placement Investors hold ~44% of voting power
- If Proposal 3 approved and all warrants exercised: Private Placement Investors hold ~61% of voting power
- Current outstanding shares: 2,061,052 as of September 30, 2026
- Board unanimously recommends FOR all proposals
- Officers and directors entered voting agreement to vote FOR Proposal 2
- Engaged Saratoga Proxy Consulting LLC for $10,000 fee
- Series M Preferred Stock: 10% dividend (12% after Sep 2027), convertible at $6.10/share, no voting rights
- Conversion price subject to adjustment with floor of $1.282 if Nasdaq requires
Financial Impact
Massive dilution: current 2,061,052 shares outstanding → up to 2,822,302 new shares issuable upon conversion/exercise of Series M Preferred and warrants (Proposal 2.8M shares if all Series M converted + all warrants exercised), potentially 44-61% of voting power shift to private placement investors. $7.75M raised now with potential $31.2M additional via Greenshoe.
Risk Factors
- Massive dilution: authorized shares increase 10x from 25M to 250M
- Potential change of control: private placement investors could hold 44-61% of voting power
- Series M Preferred Stock carries 10-12% dividend, creating cash drain or further dilution if paid in stock
- Greenshoe rights allow additional $31.2M in securities at potentially lower conversion prices
- No disclosed revenue, clinical pipeline, or operational milestones in this filing
- Conversion price of $6.10 with potential adjustment down to $1.282 floor creates toxic conversion risk if stock trades below $6.10
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001493152-26-046861 |
| Document: 0001493152-26-046861-index-headers.html | 0001493152-26-046861 |
| Document: 0001493152-26-046861-index.html | 0001493152-26-046861 |
| Document: 0001493152-26-046861.txt | 0001493152-26-046861 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | EFFECT | $5.41 | awaiting T+5 | — | $5.58 (−3.14%) |
Oct 13, 2026 14d ago | DEF 14A | $6.21 $5.41 | ▲ +12.88% | ▲ +13.34% | $5.58 (+10.14%) |
Oct 9, 2026 18d ago | S-1 | $6.80 $6.69 | ▲ +1.62% | ▲ +0.12% | $5.58 (+17.94%) |
Sep 25, 2026 4w ago | 8-K | $6.80 $6.16 | ▼ −9.41% | ▼ −10.62% | $5.58 (−17.94%) |
Sep 15, 2026 6w ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $5.58 (+38.00%) |
Sep 3, 2026 7w ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $5.58 (+2110.78%) |
Aug 14, 2026 10w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $5.58 (−1785.14%) |
May 22, 2026 22w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $5.58 (−1168.18%) |
Apr 30, 2026 25w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $5.58 (−1526.82%) |
Apr 7, 2026 29w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $5.58 (+1251.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers